What is eddii?
eddii provides comprehensive diabetes and endocrine care via an innovative app, enabling users to manage their health, connect with Dexcom CGM, and consult with endocrinologists for conditions including diabetes, weight loss, PCOS, and thyroid issues. The platform seamlessly integrates daily health tracking with expert virtual care, offering a convenient solution for individuals requiring ongoing support for their endocrine health. By employing a user-friendly interface, eddii strives to make health management both engaging and accessible, targeting individuals managing diabetes and other metabolic and endocrine conditions.
How much funding has eddii raised?
eddii has raised a total of $2.5M across 1 funding round:
Angel/Seed
$2.5M
Angel/Seed (2023): $2.5M with participation from Atento Capital, Kapor Capital, and StartUp Health
Key Investors in eddii
Atento Capital
Atento Capital is a Tulsa-based venture capital firm dedicated to unlocking the potential of early-stage founders by providing access to financial, human, and social capital. The firm focuses on supporting talented entrepreneurs from around the world, particularly those willing to relocate to Tulsa, Oklahoma, through initiatives like GridX to Tulsa.
Kapor Capital
Kapor Capital is an investment firm focused on supporting entrepreneurs from underrepresented communities in the tech industry. They provide not only financial backing but also strategic guidance and access to a robust network to help their portfolio companies succeed.
StartUp Health
StartUp Health is investing in and building a global army of Health Transformers collaborating to achieve health moonshots --- from ending cancer and curing disease, to delivering quality care to everyone in the world. Since 2012, StartUp Health has invested in nearly 400 health innovation companies across 27 countries.
What's next for eddii?
The substantial enterprise-level funding positions eddii for significant scaling and market expansion. This strategic investment will likely fuel further development of its virtual care capabilities, enhance user engagement features, and broaden its reach to a larger patient demographic seeking specialized endocrine and diabetes management. The company's trajectory suggests a focus on solidifying its position as a leader in digital chronic disease management, potentially exploring new therapeutic areas within endocrinology and forging deeper partnerships within the healthcare ecosystem.
See full eddii company page
